MedTrace Logo

Phase 1 Clinical Trial MPC-2130 Treatment of Blood Cancers / Refractory Cancer

NCT00387153 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2009-11-03

Study results available
· View outcomes & findings →

Summary

Phase 1 Open-label treatment with MPC-2130 for subjects with refractory cancer.

Conditions

Interventions

DRUG

MPC-2130

MPC-2130 10 mg/mL administered by intravenous infusion over 1-2 hours

Sponsors & Collaborators

  • Myriad Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Richard Wenstrup, MD · Myriad Therapeutics, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2006-10-31
Completion
2006-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00387153 on ClinicalTrials.gov